A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts

Yayun Liang, Benford Mafuvadze, Cynthia Besch-Williford, Salman M Hyder
  • Breast Cancer Targets and Therapy, March 2018, Dove Medical Press
  • DOI: 10.2147/bctt.s156285

The authors haven't yet claimed this publication.

open access logoRead Publication

http://dx.doi.org/10.2147/bctt.s156285

In partnership with: